Allogene療法 ALLO 深 滬
等待開盤 04-01 09:30:00 美东时间
2.44
+0.220
+9.91%
華盛通- 最 高2.495
- 今 開2.26
- 成交量 368.26万股
- 最 低 2.26
- 昨 收 2.22
- 總市值 5.95亿
- 52周最高 2.80
- 市盈率 靜 --
- 換手率 1.51%
- 52周最低 0.8621
- 委 比 -77.71%
- 總股本 2.44亿
- 歷史最高 55.00
- 量 比 0.74
- 振 幅 10.59%
- 歷史最低 0.8621
- 每 手 1
- 風險率 0.39%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) Designation to CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy
US FDA has granted RMAT designation to Caribou Biosciences' CB-011, an allogeneic anti-BCMA CAR-T cell therapy, for the treatment of relapsed or refractory multiple myeloma (r/r MM). The designation was based on promising initial clinical data, including a 92% overall response rate (ORR), 75% ≥ complete response (CR) rate, and 91% minimal residual disease (MRD) negativity in a 12-patient cohort. The ongoing CaMMouflage phase 1 clinical trial cont...
03-31 12:00
美股牛股 | 太空概念Satellogic单日暴涨38%！日本在线支付商PayPay上市累涨超50%
太空概念Satellogic单日暴涨38%！将于今日举办NASA供应商研讨会；日本在线支付商PayPay隔夜再升21%，上市累涨超50%>>
03-24 18:51
Apogee Therapeutics, Tower Semiconductor, Norwegian Cruise Line And Other Big Stocks Moving Higher On Thursday
Stocks fall, Nasdaq drops 200 points. Apogee Therapeutics (APGE) rises 19.4% on positive trial data. Satellogic (SATL), YD Bio (YDES), AXT Inc (AXTI) also see gains.
03-23 22:45
美股大行评级 | 韦德布什升美光科技目标价升至500美元，维持"跑赢大市"评级
今日重点评级关注：Piper Sandler：维持Allogene疗法"超配"评级，目标价从7美元升至8美元；B. Riley证券：维持Oncology Institute"买入"评级，目标价从6美元升至8美元
03-16 18:19
电话会总结 ｜ Allogene(ALLO)2025财年Q4业绩电话会核心要点
<span style="color:#999999;">编者按：聚焦公司高管观点与展望，深挖业绩背后的信息，助力投资者把握先机。</span><blockquote><p><span style="color:#fa1432;"><strong>业绩回顾</strong></span></p></blockquote><p>• 根据Allogene业绩会实录，以下是财务业绩回顾摘要： ## 1. 财务业绩 **现金及投资状况：** - 截至2025年12月31日，现金、现金等价物及投资总额为2.583亿美元 - 2月份从Servier仲裁托管账户收到2,370万美元 - 年初至今通过ATM股权融资工具筹集2,070万美元 **研发费用：** - 第四季度研发费用2,860万美元，其中包含250万美元非现金股权激励费用 - 2025年全年研发费用1.502亿美元，其中包含1,290万美元非现金股权激励费用 **管理费用：** - 第四季度一般管理费用1,380万美元，其中包含
03-16 14:38
Piper Sandler Maintains Overweight on Allogene Therapeutics, Raises Price Target to $8
Piper Sandler analyst Biren Amin maintains Allogene Therapeutics (NASDAQ:ALLO) with a Overweight and raises the price target from $7 to $8.
03-14 00:24
REFILE-Allogene Therapeutics Q4 net loss narrows
REFILE-Allogene Therapeutics Q4 net loss narrows Corrects March 12 story to fix typographical error in company's name in headline Overview US cell therapy developer reported Q4 net loss of $38.8 million No revenue reported for Q4 as clinical programs advance Outlook Company expects 2026 operating ca
03-13 04:29
Allogene Therapeutics Q4 EPS $(0.17) Beats $(0.22) Estimate
Allogene Therapeutics (NASDAQ:ALLO) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.22) by 21.66 percent. This is a 39.29 percent increase over losses of $(0.28) per share
03-13 04:03
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
- Pivotal Phase 2 ALPHA3 trial with Cema-Cel in first-line consolidation for LBCL aims to prevent relapse through MRD-guided treatment, expanding access beyond academic settings. - Phase 1 RESOLUTION trial with ALLO-329 for autoimmune diseases incorporates Dagger® technology to reduce lymphodepletion, with initial data expected in June 2026. - Ended Q4 2025 with $258.3 million in cash, extending cash runway into Q1 2028, supporting discipline...
03-12 20:02
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
